NCT00024011View on ClinicalTrials.gov

PS-341 in Treating Patients With Metastatic Malignant Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

September 30, 2006

Conditions
Recurrent MelanomaStage IV Melanoma
Interventions
DRUG

bortezomib

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00024011 - PS-341 in Treating Patients With Metastatic Malignant Melanoma | Biotech Hunter | Biotech Hunter